Literature DB >> 8643093

Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.

S Mankhetkorn1, F Dubru, J Hesschenbrouck, M Fiallo, A Garnier-Suillerot.   

Abstract

Multidrug resistance (MDR) is frequently associated with decreased cellular drug accumulation resulting from enhanced drug efflux. This is correlated with the presence of a membrane protein, the P-glycoprotein, which pumps a wide variety of drugs out of cells, reducing their intracellular concentration and thus their toxicity. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the P-glycoprotein-medicated efflux. Four anthracycline derivatives, doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin, which have the same amino sugar, were used to analyze the respective contribution of the kinetics of uptake and the P-glycoprotein-mediated efflux in their impaired accumulation in MDR cells. The kinetics of uptake of the four drugs vary over a very large range: the kinetics of uptake of daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin are 16, 200, and 400 times higher than that of doxorubicin, respectively. However, the four drugs are extruded by P-glycoprotein at comparable rates. The apparent Km values for P-glycoprotein-mediated transport, the intracellular free cytosolic drug concentrations at half-maximal velocity for the cell lines used, were approximately 2.2 microM for daunorubicin and and approximately 1 microM for idarubicin and 8-(S)-fluoroidarubicin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643093

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Decrease of P-glycoprotein activity in K562/ADR cells by MbetaCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts.

Authors:  Paiboon Reungpatthanaphong; Carole Marbeuf-Gueye; Laurence Le Moyec; Milena Salerno; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2004-12       Impact factor: 2.945

2.  Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

Authors:  J Tarasiuk; B Stefańska; I Plodzich; K Tkaczyk-Gobis; O Seksek; S Martelli; A Garnier-Suillerot; E Borowski
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Authors:  Pubudu M Peiris; Aaron Abramowski; James Mcginnity; Elizabeth Doolittle; Randall Toy; Ramamurthy Gopalakrishnan; Shruti Shah; Lisa Bauer; Ketan B Ghaghada; Christopher Hoimes; Susann M Brady-Kalnay; James P Basilion; Mark A Griswold; Efstathios Karathanasis
Journal:  Cancer Res       Date:  2015-01-27       Impact factor: 12.701

4.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 5.  Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.

Authors:  M M Buckley; H M Lamb
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

6.  Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers.

Authors:  J J Yang; K J Kim; V H Lee
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

7.  The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.

Authors:  Milena Salerno; Maria Petroutsa; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2002-04       Impact factor: 2.945

Review 8.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

Review 9.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

10.  Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1).

Authors:  Chantarawan Saengkhae; Chatchanok Loetchutinat; Arlette Garnier-Suillerot
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.